Quaaludes (Methaqualone): Addiction Risks, Side Effects, and History

Natalie Watkins
Brittany Ferri
Written by Natalie Watkins on 27 January 2025
Medically reviewed by Brittany Ferri on 30 January 2025

Quaaludes was a common brand name of the drug methaqualone. It was used to treat anxiety and insomnia during the 1960s and ‘70s. Highly addictive and giving a euphoric ‘high’, it became a popular recreational drug before it was banned in the 1980s following widespread misuse.

This article outlines what methaqualone is, how it works, and why it was banned.

Key takeaways:
  • Quaaludes is the brand name for methaqualone, a drug designed to help with insomnia and anxiety.
  • Methaqualone is now banned across much of the world. In the US, it is categorized as a Schedule I drug, meaning that it is not available even with a prescription.
  • Quaaludes are highly addictive and carry significant potential for dependency and harm.
a photo of multiple circular methaqualone pills floating on a white background

What is methaqualone?

Methaqualone is a hypnotic sedative drug, meaning that it helps to relieve anxiety and induces sleep. It is a CNS depressant which slows down brain activity, relaxes muscles, and lowers blood pressure and pulse rates. It was most known by the brand names Quaaludes and Sopor.

Brand names for methaqualone
Other brand names include Cateudil, Dormutil, Hyminal, Isonox, Melsed, Melsedin, Mequelone, Mequin, Methadorm, Mozambin, Optimil, Parest, Renoval, Somnafac, Toquilone Compositum, Triador, and Tuazole.

Methaqualone was also combined with diphenhydramine hydrochloride under the brand name Mandrax. This was popular in the UK and Australia but less common in the US. Both drugs were taken orally in tablet form. Quaaludes tablets contained 300 mg of methaqualone and were stamped with the number 714. Mandrax tablets contained 250 mg of methaqualone and 25 g of diphenhydramine hydrochloride.

Methaqualone was widely used recreationally.

Street names for quaaludes
It was also known as Disco Biscuits or Lemmon 714. Other common names include: Bandits, Beiruts, Blou Bulle, Disco Biscuits, Ewings, Flamingos, Flowers, Genuines, Lemmon 714, Lemons, Lennons, Lovers, Ludes, Mandies, Qua, Quaaludes, Quack, Quad, Randy Mandies, 714, Soaper, Sopes, Sporos, Vitamin Q, and Wagon Wheels

How Quaaludes (methaqualone) work

Methaqualone works similarly to benzodiazepines, although it is actually a quinazoline. It binds to gamma-aminobutyric acid (GABA) receptors in the brain and nervous system, which have a depressant effect on brain activity. It also slows the heartbeat, reduces blood pressure, and relaxes muscles.

A single 300mg dose of methaqualone can begin having an effect within 30 minutes and the effects typically last for between 5-8 hours.

History and popularity of Quaaludes

Originally being investigated as a potential new anti-malarial drug, Quaaludes were first synthesized in India in 1951. They came to the US at the start of the '60s as an effective medication to overcome insomnia and anxiety. They were believed to have few side effects, especially when compared with barbiturates, which were the main treatment for these concerns at the time.

Quaaludes became highly popular recreational drugs as a result of the euphoric ‘high’ they induced. They were easily available even after becoming Schedule II drugs in 1973, with clinics prescribing them with minimal supervision. They only fell out of favor after being moved to Schedule I in 1984.

Why quaaludes are no longer prescribed: Addiction & misuse potential

Quaaludes were prohibited due to high rates of addiction and misuse. Tolerance to methaqualone develops quickly. The prescribed dose was 300 mg but individuals who had been taking methaqualone long-term could require up to 2000 mg to achieve the same result.

Methaqualone was also highly addictive and associated with poor decision-making and motor skills. There was widespread concern around the number of fatal road traffic accidents involving the drug.

Another consideration was that other medications are available to treat both anxiety and insomnia which do not have the same euphoric effect. This makes them less likely to be used recreationally and reduces the risk of harm.

Risks and side effects of Quaaludes

Quaaludes were banned because of the risks they pose. They are highly addictive and tolerance develops quickly, meaning that increasing doses are needed to achieve the same effect.

Common side effects of methaqualone include:

  • Dizziness
  • Headache
  • Nausea
  • Nosebleeds
  • Vomiting
  • Diarrhea
  • Abdominal cramps
  • Tingling sensation in arms and legs or across the body
  • Seizures
  • Tremors
  • Hallucinations
  • Reduced heart rate
  • Slowed breathing
  • Erectile dysfunction
  • Itching
  • Rashes
  • Sweating
  • Dry mouth
  • Fatigue

Adverse health risks with methaqualone use

Methaqualone use is associated with serious medical risks. As a CNS depressant, it lowers both blood pressure and heart rate. This can lead to coma and death.

In overdose, methaqualone can cause severe muscle spasms and seizures. It can also cause kidney failure.

Methaqualone was commonly taken with marijuana or alcohol. When combined, these drugs increase the risk of serious harm.

Methaqualone was banned by Congress, effective 1984. It is a Schedule I drug and has no accepted medical use. It is illegal to manufacture, possess, or take methaqualone across the US. It is also banned across the world.

Alternatives to methaqualone for anxiety and insomnia

Anxiety and insomnia are common and the first-line treatment is usually not medication. Anyone struggling with these conditions will usually be advised to look at lifestyle factors and psychological therapies before moving on to medication. For insomnia, these lifestyle factors are sometimes known as “sleep hygiene”.

Lifestyle factors that might help anxiety and insomnia include:

  • Maintaining a comfortable temperature and reducing ambient light in the bedroom
  • Minimizing noise disturbances at night
  • Avoiding blue light (such as that from TVs, computers, or mobile phone screens) for at least an hour before bed
  • Avoiding large meals or caffeine in the hours before bed
  • Reducing alcohol intake
  • Increasing exercise earlier in the day
  • Reducing stress where possible

Psychological treatments for anxiety and insomnia can also be effective. In some cases, these will target those conditions directly, such as through cognitive behavioral therapy (CBT).

In other instances, anxiety and insomnia can be symptoms of other conditions such as depression or PTSD. Talking therapies aimed at treating those underlying conditions may provide long-term relief from anxiety and insomnia.

Medication to treat insomnia will usually only be prescribed for a short period. It can be used to overcome acute sleeplessness, for example following a bereavement, or to relieve symptoms and support longer-term care.

Benzodiazepines are usually only prescribed for a maximum of 4 weeks, due to their addictive nature. They also become less effective over time as the body builds up a tolerance to the drug.

Another group of drugs, sometimes known as Z-drugs, can be used for up to 6 months. These include zolpidem (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata).

FAQs

Common questions about Quaaludes

Are Quaaludes still prescribed today?

No. Quaaludes are no longer available on prescription in the US or most of the rest of the world.

Why were Quaaludes banned?

Quaaludes were banned because they were extremely addictive and widely misused. The effects and risks were considered to outweigh their therapeutic potential

Can you still find Quaaludes today?

There are no legal routes to find quaaludes (methaqualone) in the US today. Pills sold as Quaaludes illegally often contain other drugs with similar effects, including benzodiazepines or fentanyl.

Was this page helpful?

Your feedback allows us to continually improve our information

Resources:

  1. National Cancer Institute. (2011, February 2). NCI Dictionary of Cancer Terms - National Cancer Institute. Www.cancer.gov.
  2. Kessell, A., Marriott , P. F., & Graves, D. G. (1971). Methaqualone: Efficacy as a hypnotic and side effects. Medical Journal of Australia, 1(10), 531–534.
  3. van Zyl, E. F. (2001). A survey of reported synthesis of methaqualone and some positional and structural isomers. Forensic Science International, 122(2-3), 142–149.
  4. Herzberg, D. (2011). Blockbusters and controlled substances: Miltown, Quaalude, and consumer demand for drugs in postwar America. Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences, 42(4), 415–426.
  5. National Center for Biotechnology Information. (2025). PubChem Compound Summary for CID 6292, Methaqualone. PubChem.
  6. Chojnacka, W., Teng, J., Kim, J. J., Jensen, A. A., & Hibbs, R. E. (2024). Structural insights into GABAA receptor potentiation by Quaalude. Nature Communications, 15(1).
  7. Gerald, M. C., & Schwirian, P. M. (1973). Nonmedical use of methaqualone. Archives of General Psychiatry, 28(5), 627.
  8. Slazinski, L. (1984). Fixed Drug Eruption due to Methaqualone. Archives of Dermatology, 120(8), 1073–1073.
  9. Iber, F. L. (2020). Alcohol and Drug Abuse as Encountered in Office Practice. CRC Press.
  10. Swartzburg, M., Lieb, J., & Schwartz, A. H. (1973). Methaqualone withdrawal. Archives of General Psychiatry, 29(1), 46–46.
  11. Wetli, C. V. (1983). Changing patterns of methaqualone abuse. JAMA, 249(5), 621.
  12. World Health Organisation. (2009). Pharmacological treatment of mental disorders in primary health care. WHO Press.
  13. Krystal, A. D., Erman, M., Zammit, G. K., Soubrane, C., & Roth, T. (2008). Long-Term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: A 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep, 31(1), 79–90.

Activity History - Last updated: 30 January 2025, Published date:


Reviewer

Brittany Ferri

PhD, OTR/L

Brittany Ferri, PhD, OTR/L is an occupational therapist, health writer, medical reviewer, and book author.

Activity History - Medically Reviewed on 26 January 2025 and last checked on 30 January 2025

Medically reviewed by
Brittany Ferri

Brittany Ferri

PhD, OTR/L

Reviewer

Recovered Branding BG
Ready to talk about treatment? Call today. (855) 648-7288
Helpline Information

Calls to numbers marked with (I) symbols will be answered or returned by one of the treatment providers listed in our Terms and Conditions, each of which is a paid advertiser.

In calling the helpline you agree to our Terms and Conditions. We do not receive any fee or commission dependent upon which treatment or provider a caller chooses.

There is no obligation to enter treatment.

For any specific questions please email us at info@recovered.org

Related guides

Drug Offense Resources

11 minutes read

Drug Possession Laws

10 minutes read